{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"52.7","value":"12.5"},{"comment":"Since none of the participants had a complete response, 95% CI could not be calculated.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"CR rate is defined as percentage of participants who achieved CR. CR was assessed using Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) for participants with MZL and Consensus-Based 6th IWWM for participants with WM.\n\nPer Lugano Classification, CR= the complete disappearance of all evidence of disease and disease-related symptoms i.e., liver/spleen non palpable and normal in size and disappearance of nodules related to lymphoma.\n\nPer IWWM criteria, CR=disappearance of serum monoclonal IgM protein by immunofixation with a normal serum IgM level, liver/spleen non palpable and normal in size and disappearance of nodes related to WM.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-follicular iNHL with MZL as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG000","title":"MZL: Umbralisib"},{"description":"Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG001","title":"WM: Umbralisib"}],"paramType":"NUMBER","populationDescription":"mITT population included all participants who received at least one dose of study treatment and provided at least some post baseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years","title":"Complete Response (CR) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}